The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Detection of comprehensive oncogenic driver alteration of non-small cell lung cancer from cytology specimens by multi-gene PCR panel.
 
Tetsuya Sakai
Honoraria - AstraZeneca; Chugai Pharma; Merck; MSD; Novartis; Olympus; Thermo Fisher Scientific
Research Funding - Amgen; Daiichi Sankyo/UCB Japan; Merck
 
Hiroki Izumi
Honoraria - Bristol-Myers Squibb Japan; Chugai/Roche; Lilly; Merck; MSD; Ono Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen
Research Funding - Abbvie (Inst); Amgen (Inst); ArriVent Biopharma (Inst); AstraZeneca (Inst); Eisai/MSD (Inst); Ono Pharmaceutical (Inst); Takeda (Inst)
 
Shingo Matsumoto
Honoraria - Amgen; AstraZeneca; Chugai Pharma; Guardant Health; Lilly; Merck; Novartis; Riken; Thermo Fisher Scientific
Consulting or Advisory Role - Janssen
Research Funding - Chugai Pharma (Inst); Janssen (Inst); Merck (Inst); MSD (Inst); Novartis (Inst)
 
Hibiki Udagawa
Honoraria - Chugai Pharma; MSD; Novartis; Taiho Pharmaceutical
Research Funding - Boehringer Ingelheim (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Yu Tanaka
No Relationships to Disclose
 
Eri Sugiyama
No Relationships to Disclose
 
Shigeki Umemura
Honoraria - Chugai Pharma
 
Yoshitaka Zenke
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Lilly; MSD Oncology; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Amgen (Inst); Amgen (Inst); AstraZeneca (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Merck Serono (Inst); MSD (Inst)
 
Kiyotaka Yoh
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; MSD; Ono Pharmaceutical; Takeda
Consulting or Advisory Role - Boehringer Ingelheim
Research Funding - Abbvie (Inst); ArriVent Biopharma (Inst); AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Lilly Japan (Inst); MSD (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Koichi Goto
Honoraria - Amgen; Amoy Diagnostics; AstraZeneca Japan; Bristol-Myers Squibb K.K.; Chugai Pharma; DAIICHI SANKYO Co., Ltd.; Eisai; Guardant Health; iTeos Therapeutics Inc.; Janssen; Lilly Japan; Merck; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pharma Mar, S.A.; RIKEN GENESIS CO., LTD.; Taiho Pharmaceutical; Takeda; Thermo Fisher Scientific
Consulting or Advisory Role - Amgen; Amgen; AstraZeneca Japan; Bayer; Bristol-Myers Squibb K.K.; DAIICHI SANKYO Co., Ltd.; GlaxoSmithKline K.K.; Haihe Biopharma Co., Ltd.; Janssen; Lilly Japan; Syneos Health
Research Funding - Abbvie (Inst); Amgen (Inst); Amgen (Inst); AnHeart Therapeutics Inc. (Inst); AstraZeneca Japan (Inst); Bayer Yakuhin (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb K.K. (Inst); Chugai Pharma (Inst); CRAIF Inc. (Inst); DAIICHI SANKYO Co., Ltd. (Inst); Eisai (Inst); Guardant Health Asia, Middle East & Africa, Inc (Inst); HaiHe Biopharma Co., Ltd. (Inst); Ignyta (Inst); Janssen (Inst); Kyowa Kirin Co., Ltd. (Inst); Life Technologies (Inst); Lilly Japan (Inst); Loxo (Inst); Lunit (Inst); MEDICAL & BIOLOGICAL LABORATORIES CO., LTD. (Inst); Merck (Inst); Merus (Inst); MSD K.K. (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Precision Medicine Asia Co., Ltd. (Inst); RIKEN GENESIS CO., LTD. (Inst); Spectrum Pharmaceuticals (Inst); Sumitomo Pharma Co., Ltd. (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Turning Point Therapeutics (Inst)